Stephen Dibert to retire from Canada's MEDEC
This article was originally published in Clinica
Executive Summary
Stephen Dibert will retire as president and chief executive of MEDEC, the Canadian medical technology association, at the end of September. Mr Dibert has been at MEDEC for eight years. “Under Stephen's watch, MEDEC has doubled membership, increased its scope and reach, and successfully demonstrated the value of the medical technology industry," MEDEC chair Jim Wilson said. The MEDEC board will appoint a search committee to find the association’s next chief executive.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.